Chin Med J (Engl). 2025 Oct 31. doi: 10.1097/CM9.0000000000003832. Online ahead of print.
NO ABSTRACT
PMID:41173804 | DOI:10.1097/CM9.0000000000003832
Recent Content
- Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
- (no title)
- Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
- Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
- (no title)
- (no title)
- Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
- 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience